$223,798,184
to ALBERT B. SABIN VACCINE INSTITUTE, INC. (THE)
STRATEGIC MARBURG ADVANCED RESEARCH AND DEVELOPMENT, PREPAREDNESS, REGISTRATION, EVALUATION AND PROCUREMENT (SMART-PREP)
Verbatim from USAspending.gov. Capitalization, abbreviations, and codes are unchanged.
What the model surfaced from this award
Develop and advance Marburg virus vaccines and medical countermeasures under the SMART-PREP program.
Marburg is a rare but highly lethal hemorrhagic fever; this 10-year, $224M investment strengthens U.S. pandemic preparedness and reduces dependence on foreign vaccine capacity.
Will drive demand for clinical trial infrastructure, manufacturing scale-up, and cold-chain logistics for vaccine distribution.
Positions U.S. biotech leadership in emerging infectious disease countermeasures; reduces reliance on non-U.S. vaccine development for high-threat pathogens.
Generated by award_classification v2.1.0 via claude-haiku-4-5-20251001 on 2026-05-20. Cost: $0.003015.
- 2026-05-11THE SCOPE OF THE PROPOSED PROGRAM INCLUDES MANUFACTURE OF SABIN?S SUDAN EBOLAVIRUS VACCINE (BULK DRUG SUBSTANCE (BDS) AND FINAL DRUG PRODUCT (FDP)) TO PROVIDE DOSES THAT MAY BE USED IN THE EVENT OF AN OUTBREAK SCENARIO. THE PROPOSED EFFORT WILL UTILI$163.1M
- 2026-05-11THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE.$147.1M
- USAspending.gov — all awards for this UEI →
- SAM.gov entity registration →
- Award record ingested from usaspending. Source identifier CONT_AWD_75A50126C00001_7505_-NONE-_-NONE-.
The Buildout does not edit federal records. Any inaccuracy reflects the upstream source; it will update here when corrected there.